e13053 Background: Bortezomib, a proteosome inhibitor is an effective drug in treatment of multiple myeloma (MM). As single agent and in combination with other drugs it not only has antitumor effect but has also increased survival. There are many side effects associated with its use, including peripheral neuropathy. We report incidence of chalazion in myeloma patients treated with bortezomib. Methods: On clinical Chart review, there were 34 patients with stage 3 MM treated with bortezomib in 2010 and 2011 in a community oncology practice. There were 18 females, and 16 males. Their age ranging from 52-76 years with a median of 68years. There were 17 African American (AA) and 17 non African American (NAA) patients. 14 patients received single agent bortezomib, 10 received it in combination with dexamethasone, and other 10 in combination with lenalidomide, cyclophosphamide and steroids. All patients received bisphosphantes. Results: Four patients developed chalazion 11 to 22 months into treatment with bortezomib. Chalazion was relatively resistant to conventional therapy offered by the ophthalmologists, and persisted during therapy with bortezomib. 1 patient needed surgical intervention. 3 out of 4 patients were AA. There was no incidence of chalazion noted in solid tumor patients treated with chemotherapy that did not include bortezomib in the same time period. Conclusions: We believe, prolonged use of bortezomib is associated with 12-15% incidence of chalazion, which is relatively resistant to conventional therapy, and persist during use of bortezomib.

No abstract

No abstract

e20722 Background: Outpatient chemotherapy/biotherapy in oncologist's offices are being utilized in greater numbers, increasing the risks of acute allergic reactions. Methods: The clinical charts of patients receieving prolonged infusion chemotherapy/biotherapy treatments (1–3 hours of infusion) in a community oncologist's office setting were reviewed to determine the rate(risk), management and outcome of severe acute allergic reactions. Results: From January 2007 to December 2008, there were 1453 patient infusions conducted. 653 infusions in 2007 and 800 in 2008. All patients were premedicated with antiemetics, H2 blockers if indicated and dexamethasone. In addition starting 2008 patients also recieved diphenhydramine 25mg. There were total of 15 aute allergic reactions. 10 patients with respiratory symptoms(cough/dysponea/wheezing), 3 patients developed anaphylactic reactions, and 2 patients developed rash. Chemotherapy infusions were promptly discontinued and appropriate resusitative measures instituted. The drugs to which reactions occured included 6 to docetaxel, 3 paclitaxel, 3 carboplatin. and 3 oxaliplatin. All patients responded to resusitative measures which included IV fluids, oxygen, subcutaneous epinephrine, IV dexamethasone, and IV diphenhydramine. None required assisted ventilation or cardio version. All patients were discharged home after 1 to 3 hours of observation. Conclusions: Acute allergic reactions to anticancer therapy must be anticipated in all cases. Appropraite preventive protocols and prompt response will minimize the morbidity and eliminate mortality. No significant financial relationships to disclose.

No abstract